Cite
Bariola JR, McCreary EK, Wadas RJ, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021;8(7):ofab254doi: 10.1093/ofid/ofab254.
Bariola, J. R., McCreary, E. K., Wadas, R. J., Kip, K. E., Marroquin, O. C., Minnier, T., Koscumb, S., Collins, K., Schmidhofer, M., Shovel, J. A., Wisniewski, M. K., Sullivan, C., Yealy, D. M., Nace, D. A., Huang, D. T., Haidar, G., Khadem, T., Linstrum, K., Seymour, C. W., Montgomery, S. K., Angus, D. C., & Snyder, G. M. (2021). Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open forum infectious diseases, 8(7), ofab254. https://doi.org/10.1093/ofid/ofab254
Bariola, J Ryan, et al. "Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection." Open forum infectious diseases vol. 8,7 (2021): ofab254. doi: https://doi.org/10.1093/ofid/ofab254
Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, Koscumb S, Collins K, Schmidhofer M, Shovel JA, Wisniewski MK, Sullivan C, Yealy DM, Nace DA, Huang DT, Haidar G, Khadem T, Linstrum K, Seymour CW, Montgomery SK, Angus DC, Snyder GM. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254. eCollection 2021 Jul. PMID: 34250192; PMCID: PMC8241472.
Copy
Download .nbib